Mechanical load increases in bone formation via a Sclerostin-independent pathway

Journal of Bone and Mineral Research

Volumn 29, Issue 11, 2014, Pages 2456-2467

  Morse, Alyson ^a,b   McDonald, Michelle Maree ^c   Kelly, Natalie H ^d   Melville, Katherine M ^d   Schindeler, Aaron ^a,b   Kramer, Ina ^e   Kneissel, Michaela ^e   Van Der Meulen, Marjolein C H ^d,f   Little, David Graham ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d Cornell University   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

^f HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Bone; Loading; Mechanotransduction; Sclerostin; Unloading; WNT

Indexed keywords

BOTULINUM TOXIN; SCLEROSTIN; GLYCOPROTEIN; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE STRESS; CONTROLLED STUDY; CORTICAL BONE; FEMALE; GASTROCNEMIUS MUSCLE; MECHANOTRANSDUCTION; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OUTCOME ASSESSMENT; PARALYSIS; PERIOSTEUM; QUADRICEPS FEMORIS MUSCLE; TIBIA; TRABECULAR BONE; ANIMAL; BONE DEVELOPMENT; BONE MINERALIZATION; CHEMICALLY INDUCED; DEFICIENCY; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PHYSIOLOGY; WEIGHT BEARING;

ANIMALS; BOTULINUM TOXINS; CALCIFICATION, PHYSIOLOGIC; FEMALE; GLYCOPROTEINS; MECHANOTRANSDUCTION, CELLULAR; MICE; MICE, KNOCKOUT; OSTEOGENESIS; PARALYSIS; PERIOSTEUM; TIBIA; WEIGHT-BEARING;

EID: 84920159820     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2278     Document Type: Article

References (50)

1. Poole KE, van Bezooijen RL, Loveridge N, et al., Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005; 19 (13): 1842-4.
2. van Bezooijen RL, ten Dijke P, Papapoulos SE, Lowik CW., SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005; 16 (3): 319-27.
3. Semenov M, Tamai K, He X., SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005; 280 (29): 26770-5.
4. van Bezooijen RL, Bronckers AL, Gortzak RA, et al., Sclerostin in mineralized matrices and van Buchem disease. J Dental Res. 2009; 88 (6): 569-74.
5. Jager A, Gotz W, Lossdorfer S, Rath-Deschner B., Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res. 2010; 45 (2): 246-54.
6. van Bezooijen RL, Roelen BA, Visser A, et al., Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. The Journal of experimental medicine. 2004; 199 (6): 805-14.
7. Glass DA 2nd, Bialek P, Ahn JD, et al., Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8 (5): 751-64.
8. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG., Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. Journal of cell science. 2006; 119 (Pt 7): 1283-96.
9. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ., Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011; 6 (10): e25900.
10. Kramer I, Halleux C, Keller H, et al., Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Molecular and cellular biology. 2010; 30 (12): 3071-85.
11. Staehling-Hampton K, Proll S, Paeper BW, et al., A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. American journal of medical genetics. 2002; 110 (2): 144-52.
12. Balemans W, Ebeling M, Patel N, et al., Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human molecular genetics. 2001; 10 (5): 537-43.
13. Gardner JC, van Bezooijen RL, Mervis B, et al., Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab. 2005; 90 (12): 6392-5.
14. Loots GG, Kneissel M, Keller H, et al., Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005; 15 (7): 928-35.
15. Kramer I, Kneissel M., The high bone mass phenotype of Sost deficient mice is characterized by progressive increase in bone thickness, mineralization and predicted cortical bone strength in a gene dosage unrelated manner. Bone. 2008; 42 (Suppl 1): S57.
16. Li X, Ominsky MS, Niu QT, et al., Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23 (6): 860-9.
17. Li X, Warmington KS, Niu QT, et al., Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 25 (12): 2371-80.
18. Li X, Ominsky MS, Warmington KS, et al., Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009; 24 (4): 578-88.
19. Li X, Warmington KS, Niu QT, et al., Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010; 25 (12): 2647-56.
20. Ominsky MS, Vlasseros F, Jolette J, et al., Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010; 25 (5): 948-59.
21. Padhi D, Jang G, Stouch B, Fang L, Posvar E., Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011; 26 (1): 19-26.
22. McClung MR, Grauer A, Boonen S, et al., Romosozumab in postmenopausal women with low bone mineral density. The New England journal of medicine. 2014; 370: 412-20.
23. Moustafa A, Sugiyama T, Prasad J, et al., Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered. Osteoporosis Int. 2011; 1-10.
24. Robling AG, Niziolek PJ, Baldridge LA, et al., Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283 (9): 5866-75.
25. Lin C, Jiang X, Dai Z, et al., Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009; 24 (10): 1651-61.
26. Spatz JM, Ellman R, Cloutier AM, et al., Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res. 2013; 28 (4): 865-74.
27. Tu X, Rhee Y, Condon KW, et al., Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012; 50 (1): 209-17.
28. Chang MK, Kramer I, Keller H, et al., Reversing LRP5-dependent osteoporosis and SOST-deficiency induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res. 2013.
29. van Lierop A, Moester M, Hamdy N, Papapoulos S., Serum Dickkopf 1 Levels in Sclerostin Deficiency. J Clin Endocrinol Metab. 2013; 99: 252-6.
30. Liedert A, Wagner L, Seefried L, Ebert R, Jakob F, Ignatius A., Estrogen receptor and Wnt signaling interact to regulate early gene expression in response to mechanical strain in osteoblastic cells. Biochem Biophys Res Commun. 2010; 394 (3): 755-9.
31. Kramer I, Loots GG, Studer A, Keller H, Kneissel M., Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25 (2): 178-89.
32. Lynch ME, Main RP, Xu Q, et al., Cancellous bone adaptation to tibial compression is not sex dependent in growing mice. J Appl Physiol. 2010; 109 (3): 685-91.
33. Fritton JC, Myers ER, Wright TM, van der Meulen MC., Bone mass is preserved and cancellous architecture altered due to cyclic loading of the mouse tibia after orchidectomy. J Bone Miner Res. 2008; 23 (5): 663-71.
34. Fritton JC, Myers ER, Wright TM, van der Meulen MC., Loading induces site-specific increases in mineral content assessed by microcomputed tomography of the mouse tibia. Bone. 2005; 36 (6): 1030-8.
35. Gross TS, Edwards JL, McLeod KJ, Rubin CT., Strain gradients correlate with sites of periosteal bone formation. J Bone Miner Res. 1997; 12 (6): 982-8.
36. Mosley JR, Lanyon LE., Strain rate as a controlling influence on adaptive modeling in response to dynamic loading of the ulna in growing male rats. Bone. 1998; 23 (4): 313-8.
37. Torrance AG, Mosley JR, Suswillo RF, Lanyon LE., Noninvasive loading of the rat ulna in vivo induces a strain-related modeling response uncomplicated by trauma or periostal pressure. Calcif Tissue Int. 1994; 54 (3): 241-7.
38. Mosley JR, March BM, Lynch J, Lanyon LE., Strain magnitude related changes in whole bone architecture in growing rats. Bone. 1997; 20 (3): 191-8.
39. Macias BR, Aspenberg P, Agholme F., Paradoxical Sost gene expression response to mechanical unloading in metaphyseal bone. Bone. 2013; 53 (2): 515-9.
40. Gaudio A, Pennisi P, Bratengeier C, et al., Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab. 2010; 95 (5): 2248-53.
41. Spatz JM, Fields EE, Yu EW, et al., Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab. 2012; 97 (9): E1736-40.
42. Price JS, Sugiyama T, Galea GL, Meakin LB, Sunters A, Lanyon LE., Role of Endocrine and Paracrine Factors in the Adaptation of Bone to Mechanical Loading. Curr Osteoporos Rep. 2011; 9: 76-82.
43. Bonewald LF, Johnson ML., Osteocytes, mechanosensing and Wnt signaling. Bone. 2008; 42 (4): 606-15.
44. Zaman G, Saxon LK, Sunters A, et al., Loading-related regulation of gene expression in bone in the contexts of estrogen deficiency, lack of estrogen receptor alpha and disuse. Bone. 2010; 46 (3): 628-42.
45. Sunters A, Armstrong VJ, Zaman G, et al., Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor alpha-mediated control of insulin-like growth factor (IGF) I receptor sensitivity to Ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of beta-catenin signaling. J Biol Chem. 2010; 285 (12): 8743-58.
46. Gross TS, Srinivasan S, Liu CC, Clemens TL, Bain SD., Noninvasive loading of the murine tibia: an in vivo model for the study of mechanotransduction. J Bone Miner Res. 2002; 17 (3): 493-501.
47. Kesavan C, Wergedal JE, Lau KH, Mohan S., Conditional disruption of IGF-I gene in type 1alpha collagen-expressing cells shows an essential role of IGF-I in skeletal anabolic response to loading. American journal of physiology Endocrinology and metabolism. 2011; 301 (6): E1191-7.
48. De Souza RL, Matsuura M, Eckstein F, Rawlinson SC, Lanyon LE, Pitsillides AA., Non-invasive axial loading of mouse tibiae increases cortical bone formation and modifies trabecular organization: a new model to study cortical and cancellous compartments in a single loaded element. Bone. 2005; 37 (6): 810-8.
49. Warner SE, Sanford DA, Becker BA, Bain SD, Srinivasan S, Gross TS., Botox induced muscle paralysis rapidly degrades bone. Bone. 2006; 38 (2): 257-64.
50. Marchand-Libouban H, Le Drevo MA, Chappard D., Disuse induced by Botulinum toxin affects the bone marrow expression profile of bone genes leading to a rapid bone loss. J Musculoskelet Neuronal Interact. 2013; 13 (1): 27-36.